How does jaypirca treat mantle cell lymphoma?

How does Jaypirca stop MCL cells from dividing?

Jaypirca uses pirtobrutinib to block BTK, the protein most MCL cells rely on to survive and multiply. By binding to the active site of BTK, Jaypirca stops the signals that keep cancer cells alive. This is different from earlier BTK inhibitors because it works even when the C481S mutation develops, which usually makes other drugs fail.

Can patients who failed ibrutinib or acalabrutinib still use Jaypirca?

Yes. Clinical data show Jaypirca remains active in patients whose MCL returned or progressed after first-line BTK inhibitors. The approved indication covers relapsed or refractory MCL after two or more therapies, which often includes prior BTK inhibitor exposure. Data from the BRUIN trial showed an overall response rate of 57% in patients who had previously used BTK inhibitors.

How long does Jaypirca stay in the system?

Jaypirca has a half-life of about 19 hours, so daily dosing keeps blood levels steady. The 200 mg once-daily schedule is chosen to cover the BTK target throughout the day. Patients take tablets orally and can with or without food.

What happens if the C481S mutation develops during treatment?

Jaypirca bypasses the C481S mutation because it binds differently than ibrutinib or acalabrutinib. The non-covalent binding mechanism allows it reversible attachment to BTK, so it still works when other BTK inhibitors fail. Data suggest patients who acquired this mutation during previous treatment still responded to pirtobrutinib.

What are the common side effects patients report?

Patients using Jaypirca for MCL report fatigue, diarrhea, and infection risk. Infection is the most frequent grade 3-4 adverse event. Infection risk requires monitoring and sometimes prophylactic antibiotics. Neutropenia and bruising are also common, but less than in earlier BTK inhibitors.

When does Jaypirca's exclusivity expire?

Exclusivity granted under the NCE designation expires January 2028. Patent protection is estimated to expire in 2034 or 2035. DrugPatentWatch.com reports the full list of patents covering pirtobrutinib and the estimated dates [1].